Is Sanofi ADR Stock a Good Investment?

Sanofi ADR Investment Advice

  SNY
To provide specific investment advice or recommendations on Sanofi ADR stock, we recommend investors consider the following general factors when evaluating Sanofi ADR. This will help you to make an informed decision on whether to include Sanofi ADR in one of your diversified portfolios:
  • Examine Sanofi ADR's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
  • Research Sanofi ADR's leadership team and their track record. Good management can help Sanofi ADR navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
  • Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Sanofi ADR's business and its evolving consumer preferences.
  • Compare Sanofi ADR's performance and market position to its competitors. Analyze how Sanofi ADR is positioned in terms of product offerings, innovation, and market share.
  • Check if Sanofi ADR pays a dividend and its dividend yield and payout ratio.
  • Review what financial analysts are saying about Sanofi ADR's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Sanofi ADR stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Sanofi ADR is a good investment.
 
Sell
 
Buy
Hold
Our recommendation module provides unbiased trade recommendation that can be used to complement current average analyst sentiment on Sanofi ADR. Our recommendation engine provides an advice for the company potential to grow from the perspective of an investor's risk tolerance and investing horizon. To make sure Sanofi ADR is not overpriced, please validate all Sanofi ADR fundamentals, including its ebitda, target price, last dividend paid, as well as the relationship between the current ratio and working capital . Given that Sanofi ADR has a price to book of 1.73 X, we advise you to double-check Sanofi ADR market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your current risk tolerance and investing horizon.

Market Performance

OKDetails

Volatility

Very steadyDetails

Hype Condition

Low keyDetails

Current Valuation

UndervaluedDetails

Odds Of Distress

Very SmallDetails

Economic Sensitivity

Slowly supersedes the marketDetails

Investor Sentiment

ImpartialDetails

Analyst Consensus

Strong BuyDetails

Financial Strenth (F Score)

StrongDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails

Examine Sanofi ADR Stock

Researching Sanofi ADR's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 1.73. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sanofi ADR has Price/Earnings To Growth (PEG) ratio of 0.82. The entity last dividend was issued on the 9th of May 2024. The firm had 5:1 split on the 30th of September 2013.
To determine if Sanofi ADR is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sanofi ADR's research are outlined below:
Sanofi ADR is unlikely to experience financial distress in the next 2 years
Sanofi ADR has a strong financial position based on the latest SEC filings
Latest headline from gurufocus.com: Euroapi SA Earnings Call Highlights Navigating Challenges with Strategic ...

Sanofi ADR Quarterly Gross Profit

14.36 Billion

Sanofi ADR uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sanofi ADR. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sanofi ADR's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
1st of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
1st of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View
Earnings surprises can significantly impact Sanofi ADR's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Sanofi ADR's investors have experienced.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2007-02-13
2006-12-310.590.660.0711 
2021-07-29
2021-06-300.750.830.0810 
2018-04-27
2018-03-310.690.770.0811 
2018-02-07
2017-12-310.70.62-0.0811 
2007-10-31
2007-09-300.850.940.0910 
2006-10-31
2006-09-300.710.80.0912 
2006-05-05
2006-03-310.880.970.0910 
2020-04-24
2020-03-310.790.90.1113 

Know Sanofi ADR's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Sanofi ADR is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sanofi ADR backward and forwards among themselves. Sanofi ADR's institutional investor refers to the entity that pools money to purchase Sanofi ADR's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Goldman Sachs Group Inc2024-06-30
3.3 M
Envestnet Asset Management Inc2024-06-30
3.3 M
Nuveen Asset Management, Llc2024-06-30
3.3 M
Federated Hermes Inc2024-06-30
3.2 M
Millennium Management Llc2024-06-30
3.2 M
Franklin Resources Inc2024-06-30
M
Boston Partners Global Investors, Inc2024-06-30
M
Wells Fargo & Co2024-06-30
2.9 M
Natixis Advisors, Llc.2024-06-30
2.8 M
Dodge & Cox2024-06-30
77.1 M
Fmr Inc2024-06-30
15.2 M
Note, although Sanofi ADR's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Sanofi ADR's market capitalization trends

The company currently falls under 'Mega-Cap' category with a total capitalization of 138.25 B.

Market Cap

61.76 Billion

Sanofi ADR's profitablity analysis

Last ReportedProjected for Next Year
Return On Tangible Assets 0.10  0.14 
Return On Capital Employed 0.09  0.14 
Return On Assets 0.04  0.08 
Return On Equity 0.07  0.13 
The company has Net Profit Margin of 0.09 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.14 %, which entails that for every 100 dollars of revenue, it generated $0.14 of operating income.
Determining Sanofi ADR's profitability involves analyzing its financial statements and using various financial metrics to determine if Sanofi ADR is a good buy. For example, gross profit margin measures Sanofi ADR's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sanofi ADR's profitability and make more informed investment decisions.

Sanofi ADR's Earnings Breakdown by Geography

Please note, the imprecision that can be found in Sanofi ADR's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sanofi ADR. Check Sanofi ADR's Beneish M Score to see the likelihood of Sanofi ADR's management manipulating its earnings.

Evaluate Sanofi ADR's management efficiency

Sanofi ADR has Return on Asset of 0.0416 % which means that on every $100 spent on assets, it made $0.0416 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0582 %, implying that it generated $0.0582 on every 100 dollars invested. Sanofi ADR's management efficiency ratios could be used to measure how well Sanofi ADR manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.14 in 2024. Return On Capital Employed is likely to rise to 0.14 in 2024. At this time, Sanofi ADR's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 1.6 B in 2024, whereas Total Assets are likely to drop slightly above 88.7 B in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 29.70  31.19 
Tangible Book Value Per Share 0.31  0.33 
Enterprise Value Over EBITDA 9.49  12.27 
Price Book Value Ratio 1.53  1.45 
Enterprise Value Multiple 9.49  12.27 
Price Fair Value 1.53  1.45 
Enterprise Value109.5 B66.5 B
The analysis of Sanofi ADR's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Sanofi ADR's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Sanofi Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Dividend Yield
0.0369
Forward Dividend Yield
0.0369
Forward Dividend Rate
2.04
Beta
0.423

Basic technical analysis of Sanofi Stock

As of the 11th of October 2024, Sanofi ADR has the Semi Deviation of 0.989, risk adjusted performance of 0.0821, and Coefficient Of Variation of 1039.5. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sanofi ADR, as well as the relationship between them.

Sanofi ADR's Outstanding Corporate Bonds

Sanofi ADR issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Sanofi ADR uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Sanofi bonds can be classified according to their maturity, which is the date when Sanofi ADR has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Understand Sanofi ADR's technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Sanofi ADR's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

Consider Sanofi ADR's intraday indicators

Sanofi ADR intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Sanofi ADR stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Sanofi ADR Corporate Filings

6K
2nd of October 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
28th of June 2024
Other Reports
ViewVerify
13A
31st of May 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
28th of May 2024
Other Reports
ViewVerify
Sanofi ADR time-series forecasting models is one of many Sanofi ADR's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Sanofi ADR's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Sanofi Stock media impact

Far too much social signal, news, headlines, and media speculation about Sanofi ADR that are available to investors today. That information is available publicly through Sanofi media outlets and privately through word of mouth or via Sanofi internal channels. However, regardless of the origin, that massive amount of Sanofi data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Sanofi ADR news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Sanofi ADR relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Sanofi ADR's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Sanofi ADR alpha.

Sanofi ADR Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Sanofi ADR can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Sanofi ADR Historical Investor Sentiment

Investor biases related to Sanofi ADR's public news can be used to forecast risks associated with an investment in Sanofi. The trend in average sentiment can be used to explain how an investor holding Sanofi can time the market purely based on public headlines and social activities around Sanofi ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Sanofi ADR's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Sanofi ADR and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Sanofi ADR news discussions. The higher the estimate score, the more favorable the investor's outlook on Sanofi ADR.

Sanofi ADR Corporate Management

Roy PapatheodorouExecutive CounselProfile
FranoisXavier RogerChief OfficerProfile
Paul HudsonCEO DirectorProfile
Madeleine RoachExecutive OperationsProfile
Pierre ChancelSenior MarketingProfile
Bruno MnardChief officerProfile
Dante BeccariaGlobal VPProfile

Additional Tools for Sanofi Stock Analysis

When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.